Dr. Martens (LON:DOCS) Given "Buy" Rating at Berenberg Bank

Key Points

• Berenberg Bank reaffirmed a "Buy" on Dr. Martens with a GBX 114 price target, which the note says implies about a 76.74% potential upside from the current share price.
• Analyst views are mixed—two Buy and two Hold—while consensus data lists a "Moderate Buy" rating and a consensus target price of GBX 3,057; Royal Bank of Canada reiterated a "sector perform" rating.
• Shares trade around GBX 64.50 (1‑year range GBX 52.50–100.87) with a market cap of £623.6m and elevated metrics (P/E ~37.9, debt/equity ~120.7); insider Ije Nwokori recently sold 204,051 shares at GBX 66.

Dr. Martens (LON:DOCS - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at Berenberg Bank in a research note issued on Wednesday,Digital Look reports. They currently have a GBX 114 price target on the stock. Berenberg Bank's target price would indicate a potential upside of 76.74% from the stock's current price.

Separately, Royal Bank Of Canada reiterated a "sector perform" rating on shares of Dr. Martens in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 3,057.

Dr. Martens Trading Up 3.9%

Shares of DOCS opened at GBX 64.50 on Wednesday. Dr. Martens has a 1-year low of GBX 52.50 and a 1-year high of GBX 100.87. The company has a 50-day moving average of GBX 64.79 and a 200 day moving average of GBX 73.36. The firm has a market capitalization of £623.55 million, a price-to-earnings ratio of 37.94, a PEG ratio of 6.40 and a beta of 0.24. The company has a debt-to-equity ratio of 120.66, a current ratio of 2.18 and a quick ratio of 1.13.

Insiders Place Their Bets

In related news, insider Ije Nwokori sold 204,051 shares of Dr. Martens stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of GBX 66, for a total transaction of £134,673.66. In the last three months, insiders have bought 902 shares of company stock worth $60,382. Company insiders own 2.81% of the company's stock.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.